J&J plans to sell LifeScan for $2.1bn

21-03-2018

J&J plans to sell LifeScan for $2.1bn

Johnson & Johnson (J&J) has revealed plans to sell LifeScan, its blood glucose monitoring unit, for $2.1 billion.


Johnson & Johnson, mergers & acquisitions, Platinum Equity, blood glucose monitoring, diabetes, medical devices

LSIPR